Global Hepatitis C (HCV) Treatment Market

HCV market was valued at $12.5bn in 2015 and is forecast to contract 4.1% CAGR between 2015 and 2024, reaching 2024 global sales of $8.2bn. The volume of HCV patients who will be treated over the next several years is expected to decline resulting in market contraction.

There are 5 key discovery programs that could disrupt the HCV landscape in the foreseeable future.  These include 1) Gilead's triplet at EASL, 2) Merck's nuke study, 3) Achillion's doublet nuke regimen, 4) Regulus' novel microRNA approach that could be used with pills, and 5) Abbvie/Enanta's next generation protease regimen.  

Merck’s Zepatier (elbasvir and grazoprevir) was approved by the FDA for the treatment of adult patients with HCV genotypes 1 and 4 in January 2016. Zepatier also produced strong Phase III data, with 95% SVR rates in most genotype 1 and 4 patient groups.

There are a number of other HCV candidates in development, including new regimens from Gilead, Abbvie, and Merck. J&J is also trying to develop an interferon free regimen.


Leave A Comment